Clinical trial Recruiting at 1 site Observational Ages 18 to 45 Women only

Predicting low blood pressure after spinal anesthesia in cesarean deliveries using neck vein collapsibility and perfusion index

Official title: The Role of Preoperative Internal Jugular Vein Collapsibility and Perfusion Index in Predicting Hypotension After Spinal Anesthesia in Elective Cesarean Sections: A Prospective Observational Study

Run by Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital · NCT07539896 · Data updated 2026-11-12

This study tests whether preoperative neck vein collapsibility and a pulse oximetry-based perfusion index can predict post-spinal hypotension in women undergoing elective cesarean sections.

More Cesarean Birth trials

Quick facts

Study typeObservational
Ages18 Years to 45 Years
SexWomen only
Enrollment110 (estimated)
SponsorDr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Academic / other
Locations1 site (Muğla, Muğla)
StatusRecruiting
StartedApril 25, 2026
Main results expectedNovember 25, 2026
Study endsDecember 25, 2026
Registry record updatedOctober 28, 2026
Trial IDNCT07539896 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults 18–45 with singleton pregnancies undergoing elective cesarean delivery under planned spinal anesthesia, ASA II.

Probably not a fit

Patients with hypertensive disorders, significant cardiac disease, pulmonary hypertension, or conditions preventing neck ultrasound assessment may not benefit or be excluded.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, prospective observational study in women undergoing elective cesarean delivery with spinal anesthesia. Researchers will measure baseline perfusion index from pulse oximetry and ultrasound-derived internal jugular vein collapsibility index before anesthesia. They will then monitor for the development of post-spinal hypotension and assess how well the two measures predict it, alone or in combination. The goal is to identify patients at higher risk so clinicians can tailor management to maintain maternal hemodynamic stability. No interventions beyond standard care are described; the study focuses on predictive accuracy.

Why it matters

Potential benefit: If successful, the findings could help clinicians anticipate PSH and optimize preventive strategies for at-risk patients.

How similar studies have gone: Previous research has explored ultrasound or perfusion metrics to predict hemodynamic changes, but combining IJV collapsibility with perfusion index represents a relatively novel approach with uncertain predictive performance.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Age 18-45 years Singleton pregnancy Scheduled for elective cesarean section Planned spinal anesthesia ASA physical status II

Exclusion Criteria:

Hypertensive disorders of pregnancy (e.g., preeclampsia, HELLP syndrome) Known significant cardiac disease or pulmonary hypertension Chronic kidney disease Hemoglobinopathies Multiple pregnancy Emergency cesarean section Conversion to general anesthesia Anatomical or pathological conditions preventing IJV ultrasound assessment -

Where it's running

  • Mugla Sitki Kocman University Training and Research Hospital
    Muğla, Muğla, Turkey (Türkiye)
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.